CN1252088C - Deer serum active polypeptide crystal preparation and its preparing method - Google Patents
Deer serum active polypeptide crystal preparation and its preparing method Download PDFInfo
- Publication number
- CN1252088C CN1252088C CN 01145708 CN01145708A CN1252088C CN 1252088 C CN1252088 C CN 1252088C CN 01145708 CN01145708 CN 01145708 CN 01145708 A CN01145708 A CN 01145708A CN 1252088 C CN1252088 C CN 1252088C
- Authority
- CN
- China
- Prior art keywords
- deer
- active polypeptide
- serum
- crystal
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000282994 Cervidae Species 0.000 title claims abstract description 75
- 210000002966 serum Anatomy 0.000 title claims abstract description 57
- 239000013078 crystal Substances 0.000 title claims abstract description 47
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 42
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 38
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 38
- 238000000034 method Methods 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 239000007924 injection Substances 0.000 claims abstract description 12
- 238000002347 injection Methods 0.000 claims abstract description 12
- 102000009027 Albumins Human genes 0.000 claims abstract description 9
- 108010088751 Albumins Proteins 0.000 claims abstract description 9
- 108010074605 gamma-Globulins Proteins 0.000 claims abstract description 6
- 108010044091 Globulins Proteins 0.000 claims abstract description 4
- 102000006395 Globulins Human genes 0.000 claims abstract description 4
- 239000008280 blood Substances 0.000 claims description 67
- 210000004369 blood Anatomy 0.000 claims description 66
- 230000000694 effects Effects 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 11
- 241000282985 Cervus Species 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 5
- 241000700605 Viruses Species 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 239000003889 eye drop Substances 0.000 claims description 3
- 230000001815 facial effect Effects 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 230000002779 inactivation Effects 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 239000000178 monomer Substances 0.000 claims description 2
- 230000000050 nutritive effect Effects 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 239000011347 resin Substances 0.000 claims description 2
- 229920005989 resin Polymers 0.000 claims description 2
- 238000007789 sealing Methods 0.000 claims description 2
- 230000011218 segmentation Effects 0.000 claims description 2
- 229910001220 stainless steel Inorganic materials 0.000 claims description 2
- 239000010935 stainless steel Substances 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 238000000194 supercritical-fluid extraction Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000002537 cosmetic Substances 0.000 abstract 1
- 241001416181 Axis axis Species 0.000 description 19
- 239000011701 zinc Substances 0.000 description 14
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 229910052725 zinc Inorganic materials 0.000 description 13
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 229940089161 ginsenoside Drugs 0.000 description 9
- 229930182494 ginsenoside Natural products 0.000 description 9
- 238000007689 inspection Methods 0.000 description 9
- 210000000936 intestine Anatomy 0.000 description 9
- 244000005706 microflora Species 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 7
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 239000010949 copper Substances 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000036737 immune function Effects 0.000 description 6
- 239000011573 trace mineral Substances 0.000 description 6
- 235000013619 trace mineral Nutrition 0.000 description 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 229910052802 copper Inorganic materials 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 244000005709 gut microbiome Species 0.000 description 5
- 229910052742 iron Inorganic materials 0.000 description 5
- 239000011572 manganese Substances 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 230000000242 pagocytic effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 108010017384 Blood Proteins Proteins 0.000 description 4
- 102000004506 Blood Proteins Human genes 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 102000004420 Creatine Kinase Human genes 0.000 description 4
- 108010042126 Creatine kinase Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052748 manganese Inorganic materials 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229910017604 nitric acid Inorganic materials 0.000 description 4
- 230000035479 physiological effects, processes and functions Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000004380 ashing Methods 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 108700031361 Brachyury Proteins 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102000002070 Transferrins Human genes 0.000 description 2
- 108010015865 Transferrins Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 150000002505 iron Chemical class 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- TVBSSDNEJWXWFP-UHFFFAOYSA-N nitric acid perchloric acid Chemical compound O[N+]([O-])=O.OCl(=O)(=O)=O TVBSSDNEJWXWFP-UHFFFAOYSA-N 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 description 1
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 description 1
- AFENDNXGAFYKQO-UHFFFAOYSA-N 2-hydroxybutyric acid Chemical compound CCC(O)C(O)=O AFENDNXGAFYKQO-UHFFFAOYSA-N 0.000 description 1
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 102000003966 Alpha-1-microglobulin Human genes 0.000 description 1
- 101800001761 Alpha-1-microglobulin Proteins 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 101710095342 Apolipoprotein B Proteins 0.000 description 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 241001019179 Cingula Species 0.000 description 1
- 229910017518 Cu Zn Inorganic materials 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 101100055841 Danio rerio apoa1 gene Proteins 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000057248 Lipoprotein(a) Human genes 0.000 description 1
- 108010033266 Lipoprotein(a) Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000007584 Prealbumin Human genes 0.000 description 1
- 108010071690 Prealbumin Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000002605 anti-dotal effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 210000003056 antler Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000000112 cooling gas Substances 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- IXZISFNWUWKBOM-ARQDHWQXSA-N fructosamine Chemical compound NC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O IXZISFNWUWKBOM-ARQDHWQXSA-N 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- QWARLPGIFZKIQW-UHFFFAOYSA-N hydrogen peroxide;nitric acid Chemical compound OO.O[N+]([O-])=O QWARLPGIFZKIQW-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002354 inductively-coupled plasma atomic emission spectroscopy Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940058690 lanosterol Drugs 0.000 description 1
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000011169 microbiological contamination Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- ZODDGFAZWTZOSI-UHFFFAOYSA-N nitric acid;sulfuric acid Chemical compound O[N+]([O-])=O.OS(O)(=O)=O ZODDGFAZWTZOSI-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Images
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention belongs to the technical field of biological products, particularly relates to a deer serum active polypeptide crystal preparation and a preparation method thereof. The active components of the preparation of the present invention comprise whole serum active polypeptide crystals, albumin active polypeptide crystals, globulin active polypeptide crystals and gamma globulin active polypeptide crystals. The active polypeptide crystals which are obtained by the method of the present invention can be made into various oral agents, external agents or injections, and can also be made into cosmetics.
Description
Technical field
The invention belongs to biological product technical field.Be specifically related to a kind of deer serum active polypeptide crystal preparation and preparation method.
Background technology
Deer is beautiful, peaceful, happy and long-lived symbol, and human have indissoluble bond with deer, and deer is precious from head to foot, particularly pilose antler, deer blood.Chinese always all are used as medicine the portion of tissue of deer, get its net effect, along with the reach of science and progress, and analysis conventional Chinese medicine, it is very necessary extracting effective ingredient.Past is used deer blood whole blood, particularly drink raw, and this is not a science, and the possibility that infects some disease is arranged.
Summary of the invention
Technical problem to be solved by this invention is that from deer blood separation and Extraction obtains active polypeptide crystal and makes biological products.
The invention provides a kind of deer serum active polypeptide crystal preparation, said preparation is made up of as active ingredient and pharmaceutical carrier deer serum active polypeptide crystal.
The active ingredient of preparation of the present invention is an active polypeptide crystal, comprises whole serum active polypeptide crystal, albumin activity polypeptide crystal, globulin activity polypeptide crystal and gamma Globulin active polypeptide crystal.
Another technical problem to be solved of the present invention has provided the preparation method of above-mentioned a kind of deer serum active polypeptide crystal preparation, and this method comprises the following steps:
1. use the no cingula pin blood bag that contains antithrombotics under healthy red deer empty stomach condition, extract male arterial blood, shake homogeneous, anti-freezing;
2. making virus detects;
3. inactivation treatment is guaranteed in the blood virus-free;
4. doing for the second time, virus detects;
5. complete red deer serum is isolated in band bag centrifugation;
6. in 100 degree hygienic condition Bechtopes, extract complete red deer serum with aseptic needle tubing, concentrate in the aseptic stainless steel vessel, sealing is taken out;
7. complete red deer serum is put into super Deep-Frozen device, do-60 ℃ and caught water in 24 hours and reach 99.8% drying regime;
8. solid crystals is crushed to the state about single crystal diameter 30A;
9. the crystal after will pulverizing is put into the overcritical next device of getting, and specifies under the specification macroporous resin son's wife configuration condition, extracts segmentation or monomer peptide matters;
10. mix with pharmaceutical carrier with the peptide matters that extracts, make the formulation deer serum active polypeptide crystal preparation.
Red deer serum extract of the present invention the results are shown in Figure 1 through the clinical assay serum protein
| Series | Numbering | Numbering | Project | Abbreviation |
| Liver function | 002 | 205 | Protein electrophoresis | EPS |
| 512 | Cholinesterase | CHE | ||
| 604 | Bile acide | TBA | ||
| 201 | Total protein | TP | ||
| 202 | Albumin | ALB | ||
| 320 | Prealbumin | PA | ||
| 506 | Gpt | ALT | ||
| 514 | Alkaline phosphatase | ALP | ||
| 603 | Conjugative bilirubin | Dbil | ||
| 602 | Total bilirubin | Tbil | ||
| 505 | Glutamyltranspeptidase | PGT | ||
| Renal function | 003 | 207 | Urea (nitrogen) | BUN |
| 211 | Creatinine | Crea | ||
| 208 | Uric acid | UA | ||
| 004 | 101 | Glucose | GLU | |
| 222 | Fructosamine | FRU | ||
| 005 | 716 | Troponin-i | TN-I | |
| 717 | Myohaemoglobin | MYO | ||
| Myocardium enzyme | 006 | 507 | Glutamic-oxal(o)acetic transaminase | AST |
| 501 | Serum lactic dehydrogenase | LDH | ||
| 508 | Phosphoric acid swashs acid kinase | CK | ||
| 510 | CK-MB | |||
| Fat | 007 | 301 | Total cholesterol | Tch |
| 313 | Cholesterol ester | ChE | ||
| 302 | Triglyceride | TG | ||
| 304 | High-density lipoprotein (HDL) | HDL | ||
| 305 | Low-density lipoprotein | LDL | ||
| 306 | APoA 1 | Apo | ||
| 307 | Apolipoprotein B | Apo |
| 314 | Lipoprotein (a) | Lpa | ||
| 008 | 517 | Amylase | AMY | |
| 509 | Lipase | LPS | ||
| Urine protein series | 009 | 373 | Urine α 1 microglobulin | A1-M |
| 265 | The urine Transferrins,iron complexes | U-Trf | ||
| 392 | Microdose urine protein | UAlb | ||
| 264 | Urine Ig-G | UigG | ||
| 258 | Acetyl ammonia glucuroide | NAG | ||
| 210 | Uric creatinine | UCR | ||
| 010 | 401 | Serum potassium | K | |
| 402 | Serum sodium | Na | ||
| 403 | Serum chloride | Cl | ||
| 011 | 404 | Calcium | Ca | |
| 405 | Phosphorus | P | ||
| 406 | Magnesium | Mg | ||
| Other | 106 | Sugar tolerance | GTT | |
| 374 | Transferrins,iron complexes | TRE | ||
| 515 | Acid phosphatase | ACP |
I. the result with 11 kinds of trace elements in ICP-AES method mensuration deer blood and products thereof is as follows:
1. experimental section
1.1. instrument and working conditions
Tianjin, island ICPQ-1000 type quantorecorder, the M-20 computer, incident power 1.2kW, transmitted power is less than 4W, cooling gas flow 11L/min, substreams amount 1.2L/min, carrier gas flux 1.0L/min, observed altitude 15mm, integral time 20s.
1.2. standardized solution and reagent
Each element standard all adopts the pure or specpure reagent of top grade to be mixed with single standard stock solution of 1mg/ml, and grouping preparation hybrid standard working solution as required wherein all contains 3% hydrochloric acid again, and used acid is that top grade is pure, and water is secondary deionized water.
1.3. specimen preparation
Method one: sample is drawn 10ml (solid takes by weighing 1.000g) move in the 100ml quartz beaker, add 1.0ml sulfuric acid and put on the hot plate 70-80 ℃ of evaporation, when treating the solution thickness, slowly rotate beaker, solution is bonded on the wall of cup, is heated to after the formation anhydrosugar starch film, elevated temperature is removed excessive acid in 500 ℃ of ashing 1 hour, take out, cooling adds 2ml (1+1) hydrochloric acid, the heating for dissolving residue, change over to then in the 10ml colorimetric cylinder, the water constant volume is to be measured.
Method one: sample is drawn 5ml (solid takes by weighing 0.5000g) in tetrafluoroethylene high-pressure sample dissolving device, add 5ml nitric acid, place a night, add 1ml perchloric acid, put into baking oven behind the lid lid, be warmed up to 150 ℃ after 2 hours 100 ℃ of heating, reheat 2 hours, take out, put coldly, slowly uncap, the high-pressure sample dissolving device is placed on following near the doing of heating (200 ℃) on the hot plate, add 1ml nitric acid and continue the heating steaming to nearly 1, add 1ml (1+1) hydrochloric acid while hot, it is to be measured to add 10ml secondary constant volume.
2. result and discussion
2.1. the method test of specimen preparation
We are respectively with wet method digestion (nitric acid-sulfuric acid, nitric acid-hydrogen peroxide), add the nitric acid vibration, methods such as the interior molten sample of nitric acid-perchloric acid of 500 ℃ of ashing samples of sulfuric acid charing and high-pressure sample dissolving device are tested, owing to contain a large amount of albumen and sugar in the deer blood product, make when wet method digests wayward, temperature is high slightly, solution flashes or device foams overflows, add nitric acid vibration meeting owing to reaction acutely sprays, then safe, easy, the difficult loss of the molten sample of nitric acid-perchloric acid in hydrochloric acid extraction and the high-pressure sample dissolving device after 500 ℃ of ashing of sulfuric acid charing.
2.2. controlled trial
Method one and method two have his own strong points, method one required time is short, pre-treatment is fast, and method two is owing to also need evaporate to dryness after the digestion so required time is long, but simple to operate, laborsaving, reagent blank is low, can prevent the loss of volatile element, and we are to usefulness method one and the method two processing respectively of deer blood, deer tire electuary, on ICP, test, as a result basically identical.
2.3. measurement result
Our employing method one is respectively to deer blood, the two anti-wine of deer blood, and deer blood oral liquor and deer tire electuary have carried out 5 times to be measured, and its mean value sees Table 1
Table 1 sample analysis result
| Element | Mg | Cr | Mn | Fc | Co | N1 | Cu | Zn | Ti | Al | P |
| Two anti-wine deer blood oral liquor deer blood deer tire electuary (μ g/g) the deer tire electuaries (μ g/g) (with milk) of deer blood | 20.60 134.0 16.60 109.0 669.1 | 0.034 0.085 0.041 0.26 1.13 | 0.106 0.877 0.024 0.67 1.55 | 1.72 7.97 345.0 32.24 43.1 | ＜0.01 ＜0.01 ＜0.01 ＜0.10 ＜0.01 | ＜0.02 ＜0.02 ＜0.02 ＜0.20 0.54 | 0.038 0.331 0.46 ＜0.10 0.67 | 1.35 3.05 3.24 7.95 29.92 | 0.011 0.32 0.017 0.65 0.33 | 0.649 8.34 0.19 9.04 54.42 | 28.65 49.32 149.0 162.6 43.59 |
2.4. the accuracy of method and precision
We have carried out mensuration 6 times to the two anti-wine of deer blood, and ice adding standard has been carried out recovery test, obtains the rate of recovery at 86.6%-99.7%, and relative standard deviation is at 2.23%-8.09%.
II. deer blood is as follows to mouse intestinal flora and Immune Effects: the deer blood traditional Chinese medical science is classified as and is strengthened the body resistance to consolidate the constitution, and the strengthening yang and invigorating kidney medicine is gone into kidney channel.Compendium of Material Medica record " deer blood has qi-restoratives, enriches blood, beneficial essence and toxicide effect, is regardless of men and women, old and young, the lifelong no disease of clothes and the effect in longevity " is considered as treasure since ancient times.Have antidotal theoretical foundation for obtaining deer blood, the present invention is intended to the research that relevant deer blood is adjusted intestinal microflora and raise immunity.
1. materials and methods
1.1. animal
The purebred small white mouse in Kunming is provided by Mudanjiang Medical College's animal center.Body weight 20-22g, male and female half and half, totally 60 are divided into 6 groups at random, 10 every group.Except that the normal control group is set, other 5 groups all cause flora imbalance with U 10149a after, be respectively model group, negative control group (natural recovering group), positive controls (the happy treatment group of beautiful pearl intestines), experimental group (Chinese medicine deer blood treatment group), immunology positive controls (ginsenoside treatment).
1.2. medicine and reagent
Deer blood (fresh sterile anticoagulation).Provide by Mudanjiang City DongNing red deer plant.The happy capsule of beautiful pearl intestines is provided lot number by Zhuhai Special Economic Zone LiZhu Medicine Group Co., Ltd: 950732.Ginsenoside is provided by Mudanjiang Medical College's research on anti-senescence, RPM11640 substratum (GT IBCD reagent company).
1.3. substratum
For separating selective medium EMB, EC, BS, LBS, the Bdb of intestinal microflora.
1.4. method
1.4.1. administration
Remove the physiological saline of control group filling with equivalent, other each group is all irritated stomach, dosage 5000mg/kg/ day with U 10149a.Reached the degree of microbiotic decontamination microbiological contamination group imbalance in continuous three days.Irritated the happy physiological saline diluent of the beautiful pearl intestines of stomach respectively on the 4th day after the moulding, dosage is 0.5ml/ day (0.2 hundred million/ml bacteria containing amount).Irritate stomach deer blood, dosage is 0.6ml/ day, administration at twice, and abdominal injection ginsenoside 0.3ml (25mg/kg), every group continued medication 7 days.
1.4.2. intestinal microflora inspection
Sample is taked: remove model group, other each group then after a course of treatment and control group all be forced to take mouse fresh excreta 0.1 gram, place in the sterile vials that contains 0.9ml diluent and granulated glass sphere (w/v1: 10), equal 200 times/minute concussion 15min.
The dilution of sample, drip and plant and cultivate: the sample of homogeneity is carried out 10 times of dilutions until 10X, select three extent of dilution of corresponding substratum, dripped to low dilution by height and plant (every dropping liquid scale of construction is 1/47ml), each extent of dilution drips three.EMB and EC substratum are inverted into 37 ℃ of cultivations, observations after 24 hours, and BS, LBS, Bdb substratum are cultivated observations after 72 hours with anaerobism filling method.
Live bacterial count: CFU/g=X * 47 * extension rate * 1/g sample, result get denary logarithm value LgCFU/g form.
The evaluation of bacterium living beings type: according to colony characteristics, smear Gram dyeing, the oxygen consumption type as preliminary evaluation after, carry out biochemical reaction and identify.
1.4.3. amynologic index detects: abdominal cavity M ψ phagocytic function is measured, the hemolytic plaque test lymphocyte transformation test, and the NK cytoactive is measured.
1.4.4. statistical procedures: canonical statistics routine processes.
2. result
2.1. respectively organize mouse faecal specimen flora detected result, see Table 2
Comparison (the Lg10 of each family's mouse faecal specimen flora detected result of table 2
n/ g sample, X ± SD)
| Group | Enterobacteria | Faecalis | Bifidus bacillus | Lactobacillus | Genera bacillus |
| The happy treatment group of the beautiful pearl intestines of normal control group model group natural recovering group deer blood treatment group ginsenoside treatment group | 8.18±0.78 6.15±0.43 6.42±0.43 8.16±0.30 8.20±0.52 8.27±0.37 | 7.11±0.85 6.49±0.42 6.73±0.33 7.04±0.35 7.01±0.40 7.08±0.51 | 9.04±0.44 8.07±0.16 8.52±0.13 9.36±0.29 9.25±0.45 9.08±0.26 | 9.35±0.43 8.16±0.20 8.04±0.18 9.41±0.23 9.32±0.61 9.21±0.48 | 9.05±0.50 8.12±0.27 8.22±0.39 9.07±.024 9.04±0.56 9.01±0.68 |
As can be seen from Table 2, the effect that deer blood is adjusted alteration of intestinal flora conforms to the effect that beautiful pearl intestines are found pleasure in, and ginsenoside also has the effect of adjusting flora imbalance.
2.2. deer blood sees Table 3 to the influence of mouse peritoneal M ψ phagocytic function
Table 3 deer blood influences X=X ± S to mouse peritoneal M ψ phagocytic function
| Group | N (only) | Dosage (ml/ only) | Phagocytic percentage |
| The happy treatment group of the beautiful pearl intestines of normal control group model group natural recovering group deer blood treatment group ginsenoside treatment group | 10 10 10 10 10 10 | 0.5ml(NS) 0.5ml(NS) 0.5ml 0.6ml 0.3ml | 36.3±2.68 34.3±2.68 35.4±1.82 47.4±2.87* 58.6±2.35*** 54.1±2.19*** |
Compare with the normal control group
* *P＜0.001
*P＜0.05
2.3. the celliferous influence of blood antagonist sees Table 4
The celliferous X=X ± S that influences of table 4 deer blood antagonist
| Group | N (only) | Dosage (ml/ only) | The plaque average |
| The happy treatment group of the beautiful pearl intestines of normal control group model group natural recovering group deer blood treatment group ginsenoside treatment group | 10 10 10 10 10 10 | 0.5ml(NS) 0.5ml(NS) 0.5ml 0.6ml 0.3ml | 634.0±89.78 561.5±90.79 608.2±101.37 887.1±148.20*** 1307.9±220.93*** 1252.9±253.80*** |
Compare with the normal control group
* *P＜0.001
2.4. deer blood sees Table 5 to the influence of mouse T lymphocyte transformation efficiency
The conversion of table 5 deer blood mouse T lymphocyte influence X=X ± S
| Group | N (only) | Dosage (ml/ only) | The plaque average |
| Normal control group model group | 10 10 | 0.5ml (NS) | 44.7±6.90 40.6±4.56 |
| The happy treatment group of the beautiful pearl intestines of natural recovering group deer blood treatment group ginsenoside treatment group | 10 10 10 10 | 0.5ml(NS) 0.5ml 0.6ml 0.3ml | 42.2±4.37 60.5±5.10*** 67.2±5.09*** 65.3±6.00*** |
Compare with the normal control group
* *P＜0.001
2.5. deer blood sees Table 6 to the active influence of NK cells in mice
Table 6 deer blood is to the X ± SD% that influences of NK cytoactive
| Group | N (only) | Dosage (ml/ only) | The plaque average |
| The happy treatment group of the beautiful pearl intestines of normal control group model group natural recovering group deer blood treatment group ginsenoside treatment group | 10 10 10 10 10 10 | 0.5ml(NS) 0.5ml(NS) 0.5ml 0.6ml 0.3ml | 22.56±1.28 20.57±2.05 20.69±1.39 30.90±1.48*** 33.02±2.16*** 32.40±1.24*** |
Compare with the normal control group
* *P＜0.001
3. discuss
This experiment causes mouse intestinal flora imbalance diarrhoea with heavy dose of U 10149a, is because destroyed normal microflora and its host's microecological balance, the result that its intestinal microflora biological barrier effect is reduced.Treat with Chinese medicine deer blood, control and improved the symptom of diarrhea of mouse, make intestinal microflora return to normal level, the non-specific phagocytic immunity function of while body, the B cell produces the immunological competence of antibody, T lymphocyte transformation rate and the test of NK cytoactive all obviously strengthen, and the result is consistent with positive controls.This proof is as the Chinese medicine of strengthening the body resistance to consolidate the constitution---and deer blood can promote growing of body normal microflora, and enhancing body's immunological function reaches the purpose of strengthening vital QI to eliminate pathogenic factors.
We are considered as indivisible complete entity with body and intravital normal microflora; existence just because of the normal microflora body just makes body obtain with fight in physical environment, existence; the marrow of motherland's medical science " in healthy tendency deposits; heresy can not be done " has promptly comprised the provide protection to the body body of normal microflora and immunologic function, and normal microflora has promoter action to immunologic function.Nerve---internal secretion---the immune crossover network of metabolism---little ecology---that has complicated mutual close ties in the humans and animals body, well-known body's immunological function is subjected to the influence of its integrality, and whether stable the and balance of organismic internal environment has inevitable inner link with the power of immunologic function.The non-specific digestive function of engulfing of M ψ is strengthened, also can strengthen its processing and antigen-presenting and produce effect of cytokines, thereby start a series of immunne responses.The NK cytoactive strengthens undoubtedly and to play an important role aspect body disease-resistant poison, the antitumor and immunomodulatory.Traditional tonic medicine can anti-disease, delay senility to help normal microflora and to strengthen that to regulate immunologic function be theory.Our experimental result shows that deer blood removes the support normal microflora, adjusts outside the effect of little ecologic disturbance, still has the effect of raise immunity.We further further investigate the mechanism of action that deer blood is helped the normal microflora raise immunity in view of the gained result remains, for " lifelong no disease longevity of deer blood clothes " of Compendium of Material Medica propose scientific evidence more fully.
III. spotted deer blood medical mechanism preliminary study is as follows:
1. material source
Tested serum specimen is all bred 8 male and healthy spotted deers of study base feedlot stable breeding, deer 3-4a in age, body weight 60-80kg from the Shijiazhuang City terrestrial wildlife.
2. detect the collection of sample
1998-06-05,14:00-17:30, deer jugular vein blood sampling on an empty stomach is put in two in the clean tube of aseptically process, a test tube anticoagulant heparin, another main separation of serum.
3. experimental technique
3.1. the inspection of blood picture
The red corpuscle number is counted at microscopically with improvement group Pasteur blood counting chamber.Other item inspection taking heparin anticoagulation 25 μ l are diluted to 6ml, measure on Hemacellplus (method is homemade) blood counting instrument.
3.2. the inspection of biochemical project
Getting deer serum 50 μ l measures with Hitachi's 7150 type automatic biochemistry analyzers (Japan produces).
3.3. the inspection of trace element
The mensuration of zinc, copper, iron, manganese, magnesium: get serum 30 μ l and produce IL VIDE022 type atomic absorption spectrophotometer with the U.S..
3.4. the inspection of total protein and protein ingredient
Total protein content is measured with the biuret colorimetry.Component protein content is measured with the cellulose acetate membrane electrophoresis method.
4. test-results
4.1. hemogram checking result:
10 hemogram checkings of 8 spotted deers the results are shown in Table 7.
3 spotted deer hemogram checkings of table 7 result (number of samples=8)
| Inspection item | Mean value | The human physiology value |
| Red corpuscle sum (ten thousand mm 3) total white blood cells (ten thousand mm 3) neutrophil, (%) lymphocyte, (%) monocyte, (%) oxyphorase, (%) born of the same parents' mean thickness, (%) mean corpuscular volume (MCV), (Fl) | 1250(1150-1550) 2000(1800-2500) 35(31-45) 51(40-56) 13(9-16) 13.5(11.5-15.5) 11.8(10.2-13.5) 40(37-47) | 450--500 1000-10000 50-70 20-40 3-8 12-16 37-49 82-92 |
| The average Hb concentration of the average Hb capacity of red corpuscle (Pg) red corpuscle (g/L) | 38.7(35.240) 970(900-1100) | 72-31 320-360 |
Deer erythrocyte number, the average Hb content of red corpuscle, the average Hb concentration of red corpuscle all are much higher than people's normal physiologic values as known from Table 7, and white corpuscle is lower than people's normal physiologic values.Powerful microscope is observed down red corpuscle and is two-sided discoid, measures diameter 6.8-4.2 μ m with micrometer.
4.2. 7 kinds of micro-check results see Table 8 in the spotted deer serum
7 kinds of micro-check results (detecting number=8) in the table 8 spotted deer serum
| Element term | Mean value | The human physiology value |
| Ca(mmol/L) P (mmol/L) Zn(μmol/L) Cu(μmol/L) Fe(μmol/L) Mn(μmol/L) Mg(μmol/L) | 2.02(2.12-1.92) 2.68(2.82-2.46) 51.3(49.1-55.2) 21.4(19.2-23.1) 255.6(230.2-268.3) 0.16(0.15-0.18) 7.97(7.25-8.15) | 2.18-2.75 0.97-1.62 7.65-22.97 14.2-20.5 10.7-26.9 0.12-0.2 0.78-1.0 |
As seen from Table 8, the phosphorus in the spotted deer serum, zinc, copper, iron, 5 kinds of trace elements of manganese all are much higher than the human serum normal value.
4.3. biochemistry detection result
With automatic biochemical analyzer enzyme in the spotted deer serum and other biochemical project detected results are seen Table 9.
Table 9 spotted deer serum biochemistry detected result (number of samples=8)
| Inspection item | Mean value | The human physiology value |
| ((((((phosphoric acid of μ/L) calculates kinases coenzyme (cholesterol (mmol/L) creatinine (μ mol/L) urea (mmol/L) of μ/L) to μ/L) α-hydroxybutyric acid dehydrogenation acid to the creatine phosphokinase of μ/L) to the alkaline phosphatase of μ/L) to the lactic dehydrogenase of μ/L) to the glutamic-pyruvic transaminase of μ/L) to glutamic-oxalacetic transaminease | 128(100-148) 65(55-75) 620(600-760) 62.7(50.2-70.1) 327(292-365) 639(580-690) 772(710-820) 1.99(1.7-2.1) 123(100-156) 7.94(6.82-8.02) | 6-37 45 114-240 15-112 25-200 72-182 0-24 2.53-5.4 62-133 2.9-7.1 |
The content of 7 kinds of main enzymes all is higher than people's normal physiologic values far away in the deer blood serum as seen from Table 9.
4.4. total serum protein, albumin, sphaeroprotein and each component protein detected result see Table 10.
Table 10 spotted deer blood total protein and each component protein measurement result (number of samples=8)
| Inspection item | Mean value | The human physiology value |
| Total protein, (g/L) albumin, (g/L) sphaeroprotein, (g/L) α 1-sphaeroprotein, (%) α 2-sphaeroprotein, (%) β-bladders is white, (%) gamma globulin, (%) | 70.4(66.5-72.5) 34.9(32-45.5) 35.5(31.5-40.5) 2(1.8-2.2) 9.4(9.0-9.8) 13.8(12.2-14.2) 25.2(24.4-26) | 60-80 10-55 20-30 0.9-3.0 1.0-4.0 6.0-14 8.0-2.0 |
As seen from Table 10, spotted deer blood total protein content is consistent with the human serum normal value, but albumin level is lower, and globulin levels is higher.Particularly gamma Globulin is 3 times of human serum normal value.
5. discuss
The successive dynasties book on Chinese herbal medicine is is all recorded and narrated fresh spotted deer blood big tonifying deficiency, benefiting essence-blood, separate beans poison poison, end pain in the back, control consumptive lung disease, haematemesis and the inferior special effect of metrorrhagia band.This paper does not have significant difference by the blood picture, biochemical indicator, trace element and the protein ingredient aspect that 8 Plain stable breeding spotted deer blood pictures, biochemical indicator, trace element and protein ingredient are detected the spotted deer that confirms that Plain stable breeding spotted deer and alternate manner are raised, so its pharmacological action is identical.
Red corpuscle is a cell maximum in the blood, and its major function is transportation oxygen and a carbonic acid gas, in the blood in 98% oxygen and the red corpuscle oxyphorase betransported with chemically combined form.Detected result confirms that the spotted deer RBC number is 3 times of human erythrocyte number, and volume has only about 4 μ m, is 1/2 of HRBC volume.In the deer blood red corpuscle number than human blood many and volume little, certainly will enlarge erythrocytic membrane area, what make blood flow oxygen can be a large amount of when the high lung of oxygen partial pressure enters red corpuscle.Whether the oxygen level in the deer blood helps its pharmacological action further to inquire into.
Enzyme is the organic catalyst with colloidal property, is produced by active cells, can play katalysis with the extracellular in cell, so claim biological catalyst.Various chemical transformation in the organism metabolism activity all are by the catalysis of enzyme institute.7 kinds of enzymes that detect in this test, the content in the deer serum all is higher than human serum far away, and is more remarkable with creatine phosphokinase (CPK), AHB (HBD), creatine phosphokinase coenzyme (CK-MB) content especially.Therefore adopt deer blood to make bulk drug and should consider how to keep enzymic activity.Otherwise will influence pharmaceutical use.
Be reported in numerous trace elements according to the World Health Organization, think have 15 kinds of needed by human now, wherein with copper, iron, manganese, zinc, calcium to organism growing development, metabolism plays an important role.They can become the moiety of the biomolecules relevant with life on the one hand, and they both can be the composition of enzyme system on the other hand, also can play a role as prothetic group in many enzymatic reactions.
Calcium, zinc, copper, iron, manganese all are higher than the normal human serum value far away in the male spotted deer deer blood, and wherein zinc element is higher than 3 times of people.Result of study is generally acknowledged both at home and abroad, and zinc is the moiety and the incitant of human body 80 plurality of enzymes.It all plays an important role to the adjusting of the generation of the androgone of humans and animals, growth, reproductive function.So there is the people to think that zinc is and vital essential element.Particularly lack zinc and can cause sterile research, the movable research that influences is paid close attention to by people more and more to learning and memory to lack zinc.The food of various additional zinc arises at the historic moment.Contain high-load zinc in the spotted deer blood, and can directly absorb for organic zinc.
Manganese element also is an important element of keeping biological activity.Animal experiment confirms: manganese element lacks can cause degeneration of testis, the sexual gland atrophy, and sexual disorder and sterile, and also do not mend the manganese way at present.
Someone reports that the content of calcium, copper, iron, zinc, manganese in the tonifying kidney and benefiting sperm medicine is all abundanter.Deer blood will better play a role as the tonifying kidney and benefiting sperm medicine.
From deer blood serum protein detected result, deer blood total protein is consistent with human blood, but sphaeroprotein particularly gamma globulin is apparently higher than the human serum normal value, this may be relevant by force with the spotted deer resistance against diseases.
Extract the active polypeptide crystal obtain with the inventive method and can be made into whole serum injection liquid, albumin injection liquid and the sphaeroprotein injection liquid that capsule, oral liquid, externally-used embrocation or paste, eye drop, whole serum injection comprise subcutaneous or intramuscular injection; Also can make facial mask, nourishing cream, nutritive medium or lipstick makeup.
Description of drawings
Fig. 1 serum protein electrophoresis figure
| The band title | ％ | Reference value % |
| Albumin Alpha 1 Alpha 2 Beta Gamma | 65,5 3,4 8,8 9,0 13,3 | 52,0-65,0 1,5-4,0 9,0-15,0 9,0-15,0 10,0-22,0 |
| A/G＝1,9 | Term of reference: 1,10-2,40 | |
Embodiment
Embodiment 1 capsule
(1) hard capsule
Prescription: full deer serum active polypeptide crystal 1000g, make 2000 of hard capsules.
Method for making: drying and crushing, cross twice 80-120 mesh sieve, make crystal even, it is qualified to inspect by ready samples, inserts in the capsulae vacuus, promptly.
Other crystal by that analogy.
(2) soft capsule
Prescription: full deer serum active polypeptide crystal 500g
PEG 400 500g
100 parts in gelatin
50 parts of glycerine
100 parts in water
Make 1000 of soft capsules
Method for making: spinning block platen press system capsule machine is finished automatically
Other crystal by that analogy.
Embodiment 2 oral liquids
Prescription: full deer serum active polypeptide crystal 200g
Water 800g
Seasonings is an amount of
Method for making: fully dissolve after-filtration, be made into 20% colloidal solution and get final product.
Embodiment 3 external applications
(1) ointment: whole serum active polypeptide crystal 10g
Lanosterol 6g
Paraffin 20g
Whiteruss 54g
Vaseline 10g
Add water equivalent
(2) liniment: whole serum active polypeptide crystal 40g
Whiteruss 10g
Water 150ml
Embodiment 4 eye drops
Whole serum active polypeptide crystal 20g
Methylcellulose gum 5g
Water 75ml
Embodiment 5 makeup
(1) nourishing cream: whole serum active polypeptide crystal 100g
Stearic acid 90g
Potassium hydroxide 5g
Propylene glycol 50g
Lanolin 20g
Hexadecanol 10g
Distilled water adds to 1000g
(2) facial mask: whole serum active polypeptide crystal 100g
30% genseng leach liquor adds to 500g
Distilled water adds to 100g again
Embodiment 6 injections: subcutaneous usefulness, muscle, vein
Whole serum active polypeptide crystal 100g
The injection liquid water adds to 500g
Method for making: omnidistance aseptic, the source of reducing phlegm and internal heat, the disallergization source is filtered can and is got final product.
Other active polypeptide crystals by that analogy.
Claims (3)
1, a kind of deer serum active polypeptide crystal preparation, it is characterized in that said preparation is made up of as activeconstituents and pharmaceutical carrier deer serum active polypeptide crystal, wherein activeconstituents comprises albumin activity polypeptide crystal, globulin activity polypeptide crystal and gamma Globulin active polypeptide crystal.
2, a kind of preparation method of deer serum active polypeptide crystal preparation is characterized in that this method comprises the following steps:
1. getting male red deer arterial blood after the extraction makes virus and detects;
2. inactivation treatment is guaranteed in the blood virus-free;
3. doing for the second time, virus detects;
4. complete red deer serum is isolated in band bag centrifugation;
5. in 100 degree hygienic condition Bechtopes, extract complete red deer serum with aseptic needle tubing, concentrate in the aseptic stainless steel vessel, sealing is taken out;
6. complete red deer serum is put into super Deep-Frozen device, do-60 ℃ and caught water in 24 hours and reach 99.8% drying regime;
7. solid crystals is crushed to the state about single crystal diameter 30A;
8. the crystal after will pulverizing is put into supercritical extraction unit, and specifies the specification macroporous resin to inhale under the symbol configuration condition, extracts segmentation or monomer peptide matters;
9. mix with pharmaceutical carrier with the peptide matters that extracts, make deer serum active polypeptide crystal preparation.
3, a kind of a kind of deer serum active polypeptide crystal as claimed in claim 1 can be made into whole serum injection liquid, albumin injection liquid and the sphaeroprotein injection liquid that capsule, oral liquid, externally-used embrocation or paste, eye drop, whole serum injection comprise subcutaneous or intramuscular injection; Also can make facial mask, nourishing cream, nutritive medium or lipstick makeup.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01145708 CN1252088C (en) | 2001-12-30 | 2001-12-30 | Deer serum active polypeptide crystal preparation and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01145708 CN1252088C (en) | 2001-12-30 | 2001-12-30 | Deer serum active polypeptide crystal preparation and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1429842A CN1429842A (en) | 2003-07-16 |
| CN1252088C true CN1252088C (en) | 2006-04-19 |
Family
ID=4678282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 01145708 Expired - Fee Related CN1252088C (en) | 2001-12-30 | 2001-12-30 | Deer serum active polypeptide crystal preparation and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1252088C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103127173B (en) * | 2013-03-06 | 2015-01-21 | 苏州市红冠庄国药饮片有限公司 | Atomizing multi-layer covering and crystallizing process for producing beer blood crystal |
| CN116942800A (en) * | 2023-07-25 | 2023-10-27 | 中科富华生物技术有限公司 | Composition for human nutrition and preparation method thereof |
-
2001
- 2001-12-30 CN CN 01145708 patent/CN1252088C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1429842A (en) | 2003-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108103017A (en) | The application of the isolation and purification method and people's umbilical cord mesenchymal stem cells excretion body of people's umbilical cord mesenchymal stem cells excretion body | |
| CN1887101A (en) | Slimming tea and its prepn | |
| CN1243559C (en) | Herbal composition and medicament against diabetes mellitus type II manufactured thereof | |
| CN101485463A (en) | Natural product composing prescription with various health-care efficacies | |
| CN106722934B (en) | Anti-aging health food containing earthworm and clam worm peptide-containing extract | |
| CN1663604A (en) | Spray for treating chronic pharyngitis | |
| CN1341444A (en) | Health-care product with function of regulating blood sugar and its preparation method | |
| CN1252088C (en) | Deer serum active polypeptide crystal preparation and its preparing method | |
| CN1256124C (en) | Blood-supplementing medicine composition | |
| CN104012982A (en) | Health care product composition with immunity increasing function, soft capsule and preparation method thereof | |
| CN1313109C (en) | Decoction preparation of semen sinapis albae, fructus perillae and semen raphani and its preparing method | |
| CN1831015A (en) | Process for extracting fructus ligustri lucidi and Radixa stragali polysaccharide, the products and application thereof | |
| CN1153591C (en) | Composite prepn for preventing and treating young animal's darrhea and its prepn process | |
| CN1488297A (en) | Health food for cancer patient and preparing method thereof | |
| CN1663606A (en) | Medicine for treating radiation diseases | |
| CN106728077B (en) | Composition with functions of regulating intestinal flora structure and preventing and treating constipation and preparation method and application thereof | |
| CN1299734C (en) | Composition of traditional Chinese medicine for large intestine hygropyretic disease and its preparation method | |
| CN102335347B (en) | Panax pseudo-ginseng and panax quinquefolium soft capsules | |
| CN100360179C (en) | Medicine for treating infantile anorexia | |
| CN101755923B (en) | Milk powder having auxiliary hypoglycemic effect | |
| CN101357145B (en) | New use of phenyl propanoid total glycoside | |
| CN1237995C (en) | Ripening agent and eliminating agent for abnormal black balliary matter and its preparation method | |
| CN101347530B (en) | Oral liquid for regulating blood fat and blood sugar | |
| CN1814221A (en) | Chinese medicine composition for treating urethra infection and preparing method | |
| CN1048879C (en) | Medicine for treating primary glomerular disease and chyluria, and its preparing process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: SUZHOU CITY HONGGUANZHUANG GUOYAO HERBAL PIECES PREPARED FOR DECOCTION CO., LTD. Effective date: 20050805 Owner name: SUZHOU CITY HONGGUANZHUANG GUOYAO HERBAL PIECES P Free format text: FORMER OWNER: SHANGHAI TIANYE MEDICAL TECHNOLOGY CO.,LTD. |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20050805 Address after: Shipu town Kunshan city Suzhou area of Jiangsu province from 214343 Ma Applicant after: Hongguangzhuang Chinese Herbal Piece Co., Ltd., Suzhou Address before: 200237, Shanghai, Minhang Jin Mei Road, Village No. 302, room 34 Applicant before: Shanghai Tianyi Medical Science & Technology Co., Ltd. Co-applicant before: Hongguangzhuang Chinese Herbal Piece Co., Ltd., Suzhou |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: SUZHOU HONGGUANZHUANG TRADITIONAL CHINESE MEDICINE Free format text: FORMER NAME: HONGGUANGZHUANG CHINESE HERBAL PIECE CO., LTD., SUZHOU |
|
| CP01 | Change in the name or title of a patent holder |
Address after: Shipu town Kunshan city Suzhou area of Jiangsu province from 214343 Ma Patentee after: SUZHOU HONGGUANZHUANG MEDICINES CO., LTD. Address before: Shipu town Kunshan city Suzhou area of Jiangsu province from 214343 Ma Patentee before: Hongguangzhuang Chinese Herbal Piece Co., Ltd., Suzhou |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060419 Termination date: 20171230 |